Table 3. TTD and OS in the overall population and in patient subgroups based on baseline brain metastases, dose modifications, and EGFR mutation(s) at initial biopsy.
| Efficacy | All evaluable patients (n=419) | Baseline brain metastasesa | Dose modification | EGFR mutationb | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes (n=168) | No (n=246) | Yes (n=253) | No (n=166) | Del19 (n=252) | No Del19 (n=163) | L858R (n=129) | No L858R (n=286) | T790M (n=7) | No T790M (n=408) | ||||
| Median TTD, months (95% CI) | 17.8 (15.6–20.5) |
14.8 (12.5–16.9) |
22.9 (18.7–32.5) |
22.2 (18.2–29.7) |
14.2 (12.5–17.0) |
20.5 (16.9–27.4) |
15.4 (12.4–18.7) |
15.4 (12.4–18.7) |
19.6 (16.9–27.3) |
8.1 (2.3–32.4) |
18.2 (16.0–21.9) |
||
| P value | – | 0.001 | 0.0004 | 0.0086 | 0.0166 | 0.0174 | |||||||
| Median OS, months (95% CI) | NR (40.3–NR) |
40.3 (27.1–40.3) |
NR (46.9–NR) |
NR (NR–NR) |
40.3 (27.1–NR) |
NR | NR | NR | NR | NR | NR | ||
| P value | – | 0.0009 | 0.0117 | – | – | – | – | – | – | ||||
a, n=414 evaluable patients; b, n=415 evaluable patients. CI, confidence interval; EGFR, epidermal growth factor receptor; NR, not reached; OS, overall survival; TTD, time-to-treatment discontinuation;